Divi's Laboratories Overview
- Founded
-
1990

- Status
-
Public
- Employees
-
16,543

- Stock Symbol
-
DIVISLAB

- Share Price
-
$41.59
- (As of Friday Closing)
Divi's Laboratories General Information
Description
Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. Most of the company's sales are generated in Europe, followed by North America, India, and Asia. Divi operates two segments: the first is Generic APIs and Nutraceuticals, and the second is Custom Synthesis of APIs, intermediates, and specialty ingredients for innovators. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Contact Information
- Divi Towers, Cyber Hills
- Gachibowli
- Hyderabad, 500032
- India
Divi's Laboratories Stock Performance
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$41.59 | $40.88 | $39.48 - $61.12 | $10.9B | 265M | 531K | $1.47 |
Divi's Laboratories Financials Summary
In Thousands, USD |
TTM 30-Sep-2022 | FY 2022 31-Mar-2022 | FY 2021 31-Mar-2021 | FY 2020 31-Mar-2020 |
---|---|---|---|---|
EV | 11,710,596 | 15,157,748 | 12,841,908 | 6,921,067 |
Revenue | 1,166,970 | 1,180,985 | 921,821 | 744,706 |
EBITDA | 499,790 | 526,983 | 385,052 | 282,135 |
Net Income | 389,742 | 397,336 | 266,706 | 193,741 |
Total Assets | 1,659,067 | 1,763,815 | 1,466,942 | 1,131,755 |
Total Debt | 405 | 487 | 658 | 5,151 |
Divi's Laboratories Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Divi's Laboratories Comparisons
Industry
Financing
Details
Divi's Laboratories Competitors (13)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Zydus Lifesciences | Corporation | Ahmedabad, India | 00000 | 000.00 | 00000000 | 000.00 |
00000000 000000 | Corporation | Tokyo, Japan | 00000 | 00000000 | ||
000000000 000000 | Corporation | Hyderabad, India | 00000 | 00000 | 000000000 | 00000 |
000000000 | Corporation | Mumbai, India | 0000 | 000000000 | ||
00000 000000000000 | Private Equity-Backed | Ahmedabad, India | 00000 | 000.00 | 00000000000 | 000.00 |
Divi's Laboratories Patents
Divi's Laboratories Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
EP-4079746-A1 | Process for the preparation of molnupiravir | Pending | 23-Apr-2021 | 0000000000 | 0 |
JP-2022167736-A | Method for manufacturing molnupiravir | Pending | 23-Apr-2021 | 0000000000 | |
US-11407779-B1 | Process for the preparation of molnupiravir | Active | 23-Apr-2021 | 00000000 | 0 |
EP-4036244-A1 | Enzymatic process for the preparation of (2s)-2-[(4r)-2-oxo-4-propyl-pyrrolidin-1-yl]butyric acid and its conversion into brivaracetam | Pending | 01-Feb-2021 | 000000000 | 0 |
JP-2022117945-A | Enzymatic process for preparation of (2s)-2-[(4r)-2-oxo-4-propyl-pyrrolidin-1-yl]butyric acid and conversion to brivaracetam thereof | Pending | 01-Feb-2021 | C12P17/10 |
Divi's Laboratories Executive Team (4)
Divi's Laboratories Board Members (9)
Name | Representing | Role | Since |
---|---|---|---|
00000000 0000 | Divi's Laboratories | Board Member | 000 0000 |
0000000 0000000000 | Divi's Laboratories | Board Member | 000 0000 |
00000000000 0000 | Divi's Laboratories | Board Member & Executive | 000 0000 |
000000 0000 00.0 | Divi's Laboratories | Board Member & Founder | 000 0000 |
000000 0000 | Divi's Laboratories | Board Member & Executive | 000 0000 |
Divi's Laboratories Signals
Divi's Laboratories Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Divi's Laboratories ESG
Risk Overview
Risk Rating
Updated March, 07, 2022
17.86 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,613
Rank
Percentile

Pharmaceuticals
Industry
00 of 1,004
Rank
Percentile

Laboratory Equipment and Services
Subindustry
00 of 70
Rank
Percentile
